Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Assembly Biosciences (ASMB) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Assembly Biosciences (ASMB) over the last 11 years, with Q3 2025 value amounting to $1.7 million.

  • Assembly Biosciences' Share-based Compensation rose 10953.58% to $1.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.0 million, marking a year-over-year increase of 1920.07%. This contributed to the annual value of $3.1 million for FY2024, which is 3905.06% down from last year.
  • As of Q3 2025, Assembly Biosciences' Share-based Compensation stood at $1.7 million, which was up 10953.58% from $834000.0 recorded in Q2 2025.
  • Over the past 5 years, Assembly Biosciences' Share-based Compensation peaked at $2.0 million during Q4 2022, and registered a low of -$286000.0 during Q1 2021.
  • For the 5-year period, Assembly Biosciences' Share-based Compensation averaged around $1.2 million, with its median value being $1.2 million (2023).
  • In the last 5 years, Assembly Biosciences' Share-based Compensation crashed by 10580.83% in 2021 and then surged by 60454.55% in 2022.
  • Quarter analysis of 5 years shows Assembly Biosciences' Share-based Compensation stood at $1.9 million in 2021, then rose by 3.5% to $2.0 million in 2022, then plummeted by 52.36% to $959000.0 in 2023, then dropped by 21.69% to $751000.0 in 2024, then soared by 122.37% to $1.7 million in 2025.
  • Its last three reported values are $1.7 million in Q3 2025, $834000.0 for Q2 2025, and $712000.0 during Q1 2025.